Report of Foreign Issuer (6-k)
02 2월 2018 - 3:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2018
Commission File Number 001-33042
ROSETTA GENOMICS LTD.
(Translation of registrant’s name
into English)
10 Plaut Street, Science Park
|
Rehovot 76706, Israel
|
(Address of Principal Executive Offices)
|
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-For Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Rosetta Genomics Ltd.
The extraordinary general
meeting of shareholders of the Rosetta Genomics Ltd. (the “Company”) that was convened on February 1, 2018 has been
adjourned to
Thursday, February 15, 2018 at 10:00 am (PT)
. The adjourned meeting will be held at the California office of
the Company at 25901 Commercentre Dr., Lake Forest, CA 92630.
The matter to be voted
upon at the adjourned meeting, and the record date for the shareholders entitled to vote at the meeting, will remain unchanged.
For information regarding the matter to be voted upon at the adjourned meeting, see the Company’s proxy statement filed on
Form 6-K with the U.S. Securities and Exchange Commission on December 28, 2017.
A copy of a letter
to shareholders regarding the adjournment of the extraordinary general meeting of shareholders of Rosetta Genomics Ltd. is filed
as Exhibit 99.1 hereto and incorporated by reference herein.
Exhibits
Exhibit
Number
|
|
Description of Exhibit
|
|
|
|
99.1
|
|
Letter to shareholders regarding the adjournment of the extraordinary general meeting of shareholders of Rosetta Genomics Ltd.
|
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ROSETTA GENOMICS LTD.
|
|
|
Date: February 1, 2018
|
By:
|
/s/ Ron Kalfus
|
|
|
Ron Kalfus
Chief Financial Officer
|
Rosetta Genomics (CE) (USOTC:ROSGQ)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
Rosetta Genomics Ltd (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Rosetta Genomics Ltd. News Articles